Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00036517
Recruitment Status : Terminated
First Posted : May 13, 2002
Last Update Posted : June 24, 2005
Information provided by:

Brief Summary:
The triple combination chemotherapy of irinotecan, 5-fluorouracil and leucovorin (CPT-11/5-FU/LV or Saltz regimen) is the treatment of choice for patients with advanced colorectal cancer. Severe diarrhea, unfortunately, is a side effect of such treatment. Preclinical studies have indicated that the botanical drug PHY906 can reduce such diarrhea without compromising the effectiveness of the chemotherapy. The primary purpose of this clinical study is to evaluate the safety, tolerability and minimum effective dose of PHY906 when administered in conjunction with the Saltz regimen.

Condition or disease Intervention/treatment Phase
Colorectal Neoplasms Diarrhea Drug: PHY906 Phase 1 Phase 2

Detailed Description:
CPT-11/5-FU/LV is an active combination agent in the treatment of colorectal cancer, but one of its dose-limiting toxicities is diarrhea. PHY906 has been shown to reduce the severity of CPT-11-induced toxicity without compromising antitumor efficacy in in vivo animal models. Additionally, there has been a long historical experience in the Far East demonstrating safety of PHY906 in humans. Thus, we are conducting this double-blind, placebo-controlled study to evaluate the safety and tolerability of PHY906. This dose escalation study will also examine the effect of PHY906 (1.2, 2.4, and 3.6 g/day) on the pharmacokinetics of CPT-11 and 5-FU after concomitant administration with CPT-11, 5-FU, and LV, and on the severity of CPT-11-induced toxicities such as diarrhea.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose Escalation, Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
Study Start Date : February 2002
Study Completion Date : March 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patients must:

  • be between 18 and 75 years of age, inclusive, at the time of enrollment.
  • have advanced colorectal carcinoma, which may be either measurable or non-measurable.
  • not have received either CPT-11, FU, or other cytotoxic chemotherapy agents in any setting (including adjuvant) within 1 year prior to screening.
  • have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • use an effective contraceptive method if the patients are of reproductive potential while enrolled in the study, since the potential effects of the herbs on a developing fetus are unknown.
  • have an estimated life expectancy of at least 20 weeks.
  • provide written informed consent.
  • have adequate organ function as indicated by the following laboratory values; these laboratory values must be obtained within 14 days prior to study enrollment:
  • Bone marrow reserve: absolute granulocyte count (AGC) more than or equal to 1.5 X 10(to the power of 9)/L, platelet count more than or equal to 100 X 10 (to the power of 9)/L, and hemoglobin level more than or equal to 9 g/dL.
  • Hepatic function: serum total bilirubin concentration no greater than 1.5 mg/dL, aspartate transaminase (AST or serum glutamic-oxaloacetic transaminase [SGOT]), and alanine transaminase (ALT or serum glutamic-pyruvic transaminase [SGPT]) levels no greater than grade 2 toxicity as determined from the NCI-CTC version 2.0.
  • Renal function: serum creatinine level no greater than grade 2 toxicity as determined from the CTC version 2.0.

Exclusion Criteria

Patients who have or are:

  • Gilbert syndrome (familial, non-hemolytic, acholuric jaundice).
  • patients with enterostomies.
  • untreated brain metastases or deteriorating neurological function after the completion of cranial irradiation.
  • a woman who is currently pregnant and/or breast-feeding.
  • active infections or any serious systemic disorder that, in the opinion of the principal investigator, are incompatible with the study product and/or procedures.
  • used an investigational agent within 4 weeks of study entry.
  • a known hypersensitivity to the study medication, its excipients, its analogs, or any of the component herbs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00036517

Layout table for location information
United States, Connecticut
VA CT Cancer Center
West Haven, Connecticut, United States, 06516
United States, New York
Weill Cornell Medical Center
New York, New York, United States, 10021
United States, South Carolina
Cancer Centers of the Carolinas
Greenville, South Carolina, United States, 29615
Sponsors and Collaborators
Layout table for investigator information
Study Director: Wayne D Brenckman, Jr., MD Inveresk Research
Layout table for additonal information Identifier: NCT00036517    
Other Study ID Numbers: PHY906-2000-1
First Posted: May 13, 2002    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: September 2004
Keywords provided by PhytoCeutica:
Stage III and Stage IV colorectal cancer
Saltz regimen
side effect
botanical drug
herbal medicine
chinese herbal medicine
traditional chinese medicine
oral dose
oral administration
concomitant use
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Signs and Symptoms, Digestive